Drug Interactions between Alunbrig and duloxetine
This report displays the potential drug interactions for the following 2 drugs:
- Alunbrig (brigatinib)
- duloxetine
Interactions between your drugs
No interactions were found between Alunbrig and duloxetine. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Alunbrig
A total of 634 drugs are known to interact with Alunbrig.
- Alunbrig is in the drug class multikinase inhibitors.
- Alunbrig is used to treat Non Small Cell Lung Cancer.
duloxetine
A total of 592 drugs are known to interact with duloxetine.
- Duloxetine is in the drug class serotonin-norepinephrine reuptake inhibitors.
-
Duloxetine is used to treat the following conditions:
- Anxiety
- Back Pain
- Bipolar Disorder (off-label)
- Chronic Fatigue Syndrome (off-label)
- Chronic Pain
- Depression
- Diabetic Peripheral Neuropathy
- Fibromyalgia
- Generalized Anxiety Disorder
- Hot Flashes (off-label)
- Major Depressive Disorder
- Osteoarthritis
- Pain (off-label)
- Peripheral Neuropathy (off-label)
- Persistent Depressive Disorder (off-label)
- Small Fiber Neuropathy (off-label)
- Somatoform Pain Disorder (off-label)
- Urinary Incontinence (off-label)
Drug and food interactions
DULoxetine food
Applies to: duloxetine
GENERALLY AVOID: Use of duloxetine in conjunction with chronic alcohol consumption may potentiate the risk of liver injury. Duloxetine alone can increase serum transaminase levels. In clinical trials, 0.3% of patients discontinued duloxetine due to liver transaminase elevations. The median time to detection was about two months. Three duloxetine-treated patients had liver injury as manifested by transaminase and bilirubin elevations, with evidence of obstruction. Substantial intercurrent ethanol use was present in each of these cases, which may have contributed to the abnormalities observed. Duloxetine does not appear to enhance the central nervous system effects of alcohol. When duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
MANAGEMENT: Due to the risk of liver injury, patients prescribed duloxetine should be counseled to avoid excessive use of alcohol. Duloxetine should generally not be prescribed to patients with substantial alcohol use.
References
- (2004) "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company
brigatinib food
Applies to: Alunbrig (brigatinib)
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of brigatinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Itraconazole, a potent CYP450 3A4 inhibitor, has been shown to double brigatinib systemic exposure (AUC) in healthy volunteers. Increased exposure to brigatinib may increase the risk of adverse effects such as nausea, vomiting, diarrhea, hypertension, bradycardia, hyperglycemia, visual disturbances, lymphopenia, anemia, and elevations in pancreatic enzymes and creatine phosphokinase.
Food does not significantly affect the oral bioavailability of brigatinib. When brigatinib was administered to healthy volunteers after a high-fat meal (920 calories; 59 g fat, 58 g carbohydrates, 40 g proteins), brigatinib peak plasma concentration (Cmax) decreased by 13% and systemic exposure (AUC) did not change compared to administration after overnight fasting.
MANAGEMENT: Brigatinib may be taken with or without food. Patients should avoid consumption of grapefruit and grapefruit juice during treatment with brigatinib.
References
- (2017) "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.